OHR Pharmaceutical Inc (NASDAQ:OHRP) an ophthalmology R&D company demonstrated additional positive results from the Phase II IMPACT study assessing OHR-102 combination therapy for the cure of the wet arrangement of age-related macular degeneration. The report was highlighted by Dr. David S. Boyer, who is an investigator in the trial.
OHR Pharmaceutical Inc (NASDAQ:OHRP) presented the positive results from OHR-102 Phase II trial at the annual meeting of AAO in Las Vegas. New report from the IMPACT trial shows that visual acuity results correlate with the composition and size of lesions in the enrollments. Previously, a positive gain in respect of visual acuity outcomes was validated in subjects with classic containing lesions.
The detailed study of lesion characteristics and related predictive impact on visual acuity outcomes showed that of the combination treatment impact on visual acuity is proportional to the size of the occult CNV, immaterial of presence of classic component. This size effect was not recorded in those subjects cured with Lucentis(R) monotherapy.
OHR Pharmaceutical Inc (NASDAQ:OHRP) reported that the occult CNV size, regardless of a classic CNV constituent, was most significant in predicting cure success with the combined treatment of OHR-102 plus Lucentis. In the subjects with occult CNV size less than 10mm2, 40% of those cured with the mentioned combination achieved a benefit of three or more than three lines of vision, against 26% of subjects enrolled in the Lucentis monotherapy arm, reflectinga 54% additional gain.
Additionally, mean benefits in visual acuity against baseline stood at +11.0 letters for the combination of OHR-102 and Lucentis combination and it came at +5.7 letters in case of Lucentis monotherapy. It clearly demonstrated a clinically meaningful gain of +5.3 letters. Notably, this group of patients highlights a larger proportion of the enrollments registered in the IMPACT study compared to the classic containing group.